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1. Introduction 
Pulmonary parenchymal complications remain the main cause of morbidity and mortality in 
human immunodeficiency virus (HIV) infected patients (McGuinness, 1997). Early diagnosis 
and treatment of these complications are important to improve survival.  
HIV impairs the immune system, leading the infected person susceptible to a variety of 
infections, called opportunistic infections, a leading cause of mortality and morbidity in 
patients with HIV/AIDS. The effect of HIV on the immune system is monitored by 
measuring the CD4 (T-helper) lymphocyte count in the blood. Depletion of CD4 cell count is 
a hallmark of disease progression in AIDS. CD4 cell count is essential to decide about the 
timing of initiation of antiretroviral therapy and for prophylaxis of opportunistic infections.  
It has been known that the lungs are principal targets of HIV-associated complications and 
persons with HIV infection are at an increased risk for opportunistic pneumonias, 
neoplasms, and other pulmonary conditions. The spectrum of pulmonary manifestations in 
patients infected with HIV is broad, including many infectious and noninfectious 
complications. Pneumonia is the leading HIV-associated infection. In a recent report in 
which 762 patients with HIV/AIDS were analyzed, pulmonary infections was found as the 
most prevalent infections (Huang et al., 2010). It is estimated that 65% of the patients 
infected with HIV will present pulmonary involvement as their first clinical manifestation of 
the syndrome and that approximately 80% of these patients will present some kind of 
pulmonary involvement in the course of the disease (Suffredini & Masur, 1988). 
This section is related with the pulmonary infectious complications of HIV/AIDS. 
2. Bacterial infections 
Bacterial respiratory infections are one of the most common causes of respiratory complaints 
in HIV-positive patients.  
Although HIV infection is most closely associated with altered cell-mediated immunity, a 
number of additional immune deficiencies may occur in association with HIV infection 
(Daley, 1993; Davis et al, 1993; Noskin & Glassroth, 1996). It usually includes a poor 
antibody response due to B cell dysfunction and defects in chemotaxis, phagocytosis and 
intracellular killing by monocytes, macrophages and neutrophils. Moreover, HIV-infected 
individuals may experience impairment of local defenses, manifested by a depression of 
specific IgA at the mucosal surfaces. These immune abnormalities all contribute to an 
increased risk of bacterial infection among HIV-infected persons. 
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Combination antiretroviral therapy (ART) is associated with a decreased risk for bacterial 
pneumonia and during the combination ART era the incidence of community-acquired 
bacterial pneumonia among HIV-infected patients has declined (Crothers et al., 2010). 
Antiretroviral regimens contain an HIV protease inhibitor (Sullivan et al., 2000) and the use 
of trimethoprim-sulfamethoxazole as prophylaxis for Pneumocystis jiroveci pneumonia may 
be associated with decreased risk for bacterial pneumonia (Kohli et al., 2006). However, 
community-acquired pneumonia represents a frequent cause of morbidity and is associated 
with an increased mortality in HIV-infected patients also in the ART era. 
Bacterial pneumonia may be the first manifestation of underlying HIV infection and thus the 
presence of HIV infection should be considered in any person presenting with bacterial 
pneumonia, especially if the individual has no other risk factors for pneumonia or if the 
pneumonia is recurrent. Recurrent bacterial pneumonia (defined as two or more episodes 
within 12 months) is included as an AIDS-defining illness in the 1993 CDC Expanded 
Surveillance Case Definition for AIDS (Centers for Disease Control and Prevention, 1993).  
The incidence of bacterial pneumonia among persons with HIV infection is greater than that 
among persons without HIV. It has been estimated that one third of all persons with AIDS 
will develop at least one episode of severe bacterial pneumonia over the course of their HIV 
infection (Noskin & Glassroth, 1996). Afessa et al. (Afessa et al., 1998) found bacterial 
pneumonia to be the most frequent pulmonary complication (42%) in an autopsy series of 
233 HIV-infected individuals. In a recent autopsy study, in which 250 autopsies of 
HIV/AIDS patients who died of acute respiratory failure was analyzed, bacterial 
bronchopneumonia was present in 36% (91 cases) (Soeiro et al., 2008). According to another 
study, the incidence of pneumococcal pneumonia is five to 18 times greater than that in the 
general population, and the development of pneumococcal septicemia is 100 times greater 
(Janoff et al., 1992). In a multicenter, prospective, observational study, Hirschtick et al. 
monitored 1130 HIV-positive and 167 HIV-negative adults for up to 64 months for 
pulmonary disease and they found that, there were 237 episodes of bacterial pneumonia 
among the HIV-positive participants (rate, 5.5 per 100 person-years), as compared with 6 
episodes among the HIV-negative participants (rate, 0.9 per 100 person years; p<0.001). 
They also showed that, the rate of bacterial pneumonia increased with decreasing CD4 
lymphocyte counts (2.3,6.8, and 10.8 episodes per 100 person-years in the strata with more 
than 500, 200 to 500, and fewer than 200 cells per cubic millimeter, respectively; p≤0.022 for 
each comparison) (Hirschtick et al., 1995). Bacterial pneumonia is more common in smokers 
with HIV than in nonsmokers and injection drug use more than doubles the risk of bacterial 
lower respiratory infections compared with those who acquired HIV through sexual 
exposure (Fangman & Sax, 2008). Other risk factors are a low socioeconomic, alcohol abuse 
status, comorbidities (including cardiovascular, renal disease malnutrition, and hepatic 
cirrhosis), low CD4 cell counts (<200 cells/ml), uncontrolled HIV replication and not 
receiving ART (Madeddu et al., 2010). 
Similar to that in the general population, Streptococcus pneumoniae and Haemophilus species 
are the most frequently identified causes of community-acquired bacterial pneumonia  
(Hirschtick et al., 1995; Madeddu et al., 2008; Schneider, 1999). Staphylococcus aureus, 
Escherichia coli, and Pseudomonas aeruginosa account for most of the remainder of cases 
(Afessa & Green, 2000; Baron & Hollander, 1993; Madeddu et al., 2008). Risk factors for S. 
aureus include recent viral or influenza infection and use of injection drugs. Methicillin-
resistant S. aureus which may be acquired in health care setting or in the community is 
increasingly common. P. aeruginosa has been increasingly recognized as an important source 
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of bacterial pneumonia in HIV-infected individuals, particularly in those with advanced 
HIV/AIDS (CD4 cell count less than 50 cells/μL), underlying structural lung disease 
(bronchiectasis), neutropenia, indwelling catheters, receipt of corticosteroid therapy, 
multiple antibiotic therapy, and severe malnutrition. Atypical pathogens such as Legionella 
pneumophila, Mycoplasma pneumoniae, and Chlamydophila species are less frequent causes of 
pneumonia (Sandkovsky et al., 2008). Other less causes of pneumonia include Rhodococcus 
equi, Nocardia species Bartonella henselae and quintana. Rhodococcus equi, an aerobic gram-
positive, may cause focal consolidation, endobronchial disease and cavitation, and is usually 
associated with low CD4 cell count (100 cells/μl) in HIV/AIDS patients. Nocardia asteroides 
may cause nodules, consolidation, cavitation, pleural effusions, empyema and intrathoracic 
lymphadenopathy in HIV-infected persons. 
In contrast with community-acquired pneumonia, the two most common bacterial causes of 
hospital- acquired pneumonia in patients with HIV are P. Aeruginosa and S. Aureus, while S 
pneumoniae and K. Pneumoniae are other relatively frequent causes (Crothers et al., 2010). 
The clinical features of bacterial pneumonia in HIV-infected persons is similar to those in 
immunocompetent persons and includes acute onset of fever, dyspnea, dry or productive 
cough, chills and chest pain. Physical findings consist of fever, tachypnea, tachycardia, rales 
or rhonchi, and other signs of consolidation and occasionally pleural effusion (Huang & 
Crothers, 2009). Bacterial pneumonia in HIV-infected patients can occur at all levels of CD4 
cell count, and an inverse relationship between the incidence of pneumonia and the CD4 cell 
count has been observed (Hirschtick et al., 1995). However, patients with higher CD4 cell 
counts are more likely to present with a typical clinical picture, in contrast, patients with low 
CD4 cell count often present an atypical clinical picture (Madeddu et al., 2010). 
The most common radiographic pattern in bacterial pneumonia is focal consolidation, which 
typically presents in either a segmental or lobar distribution (Boiselle et al., 1997; Gold et al., 
2002; Kuhlman, 1999; Selwyn et al., 1998; Sider et al. 1993). In two studies of HIV-infected 
individuals with bacterial pneumonia, focal consolidation was observed in approximately 
45–60% of patients (Boiselle et al., 1997; Magnenat et al., 1991). Most persons with S. 
pneumoniae or Haemophilus pneumonia present with unilateral, focal, segmental or lobar 
consolidation. Lobar pneumonia is seen most commonly in S. pneumoniae pneumonia. A 
variety of gram (+) and gram (-) bacteria, most commonly Staphylococcus, Streptococcus, 
Pseudomonas, Klebsiella, Enterobacter,and Haemophilus,  may cause bronchopneumonia. 
In almost half of the cases of bacterial pneumonia, a radiographic pattern other than focal 
consolidation is observed (Brecher et al., 2003). Solitary or multiple lung nodules, cavitary 
pulmonary lesions are other radiologic findings often associated with bacterial pneumonia 
in HIV-infected patients. P. aeruginosa or S. aureus are most common bacterial causes of 
cavitary nodules or cavitary consolidation, while less common bacterial causes include N. 
asteriodes and R. equi infections. HIV-infected patients had an increased risk for complicated 
parapneumonic effusions, especially if due to S. pneumoniae or S. aureus. 
Although conventional radiographs are the mainstay of imaging of bacterial respiratory 
infections in HIV-infected persons, CT provides more information about nodules, cavities, and 
pleural fluid collections. Hence, CT may be useful for further characterizing atypical 
radiographic findings, for diagnosing complications of infection such as abscess or empyema. 
The diagnostic approach to bacterial pneumonia in HIV-infected patients is similar to that of 
HIV-negative patients. Current US guidelines recommend that persons hospitalized with 
suspected bacterial pneumonia should undergo diagnostic evaluation for specific pathogens 
(Centers for Disease Control and Prevention, 2009). The diagnostic tests include gram stain 
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and culture of sputum, blood cultures and thoracentesis should be performed in patients 
with pleural effusions. Bronchoscopy should be done to support or establish correct 
diagnosis via taking wash, brush or biopsy. In patients in whom the diagnosis is unclear, 
other supplemental testing such as a modified acid-fast stain (for Nocardia and Rhodacoccus) 
or a urinary legionella antigen can be appropriate (Fangman & Sax, 2008). In pneumococcal 
pneumonia, pneumococcal urinary antigen testing offers the potential for early, specific 
diagnosis. 
Although numerous guidelines (BTS guidelines, 2001; Mandell et al., 2007; Woodhead et al., 
2005) for the management of community-acquired pneumonia (CAP) in HIV-negative 
patients have been developed by scientific societies, to date, no specific guidelines have been 
developed for HIV-infected patients. However, the principle of the treatment of bacterial 
pneumonia is similar in both HIV positive and negative patients (Fangman & Sax, 2008). 
The choice of antimicrobial agent should be based on the results of a sputum gram stain, the 
clinical and radiologic presentation, severity of the illness, presence of co-morbid disease 
and knowledge of local microbiology and resistance patterns. Duration of the therapy is 
generally similar or a bit longer than to that of HIV negative patients. 
Although the emergence of antimicrobial resistant organisms is a global problem, in HIV-
infected patients, there is limited data on the prevalence and the impact of drug resistant 
bacteria on the clinical course of the disease. The rate of penicillin-resistant S. pneumoniae in 
HIV-infected patients is reported to be higher than in HIV-noninfected patients (Madeddu 
et al., 2009). However, in a recent report, no obvious difference in pneumococci resistance 
patterns has been found between HIV-positive and negative patients (Stephan et al., 2009). 
Also, in a study in which the trend of S. pneumoniae antibiotic resistance has been evaluated, 
a near significant decrease in penicillin-resistant strains in the late-HAART compared with 
of pre and early-HAART era has been found (Grau et al., 2009). Patients on TMP-SMX 
prophylaxis for Pneumocystis pneumonia may be more likely to have penicillin and TMP-
SMX resistant S. pneumoniae.  With the widely use of TMP-SMX prophylaxis, an increase in 
resistance to TMP-SMX in other bacteria has also been reported (Marin et al., 1999). 
Prevention strategies of bacterial pneumonia should address on several problems such as 
the role of cigarette smoking, alcohol abuse and ongoing injection drug use, hepatic and 
renal comorbidities, late presentation of HIV diagnosis, highly active antiretroviral therapy 
(HAART) lack of compliance, and virus effects and immunological failure. Combination 
antiviral therapy should be considered for all patients with recurrent bacterial lower 
respiratory tract infections. HIV patients not receiving HAART are clearly at an increased 
risk of bacterial pneumonia. Vaccination strategies are still controversial in HIV infected 
individuals. On the one hand, some studies showed a good response and a reduction in new 
cases among vaccinated patients, on the other, some reports found no evidence of efficacy. 
However, pneumococcal vaccine is recommended for all HIV patients who have a CD4 cell 
count greater than 200 cells/μl. The influenza vaccine should be given to all persons with 
HIV infection annually prior to influenza season. Trimethoprim-sulfamethoxazole, when 
administered daily for PCP prophylaxis, can reduce the frequency of bacterial respiratory 
infections (French et al., 2000; Loeliger et al., 1995; Rodriguez-Barradas et al., 1992).  
3. Mycobacterial infections 
Tuberculosis (TB) remains an important cause of morbidity and mortality among persons 
with HIV infection. Pulmonary TB is still the commonest form. In HIV infected persons, the 
www.intechopen.com
 
AIDS and Opportunistic Infections 91 
estimated annual risk of developing active TB ranges from 35 to 162 per 1,000 person-years, 
compared to 12.9 per 1,000 person-years for those without HIV infection (Centers for 
Disease Control and Prevention, 2009). The World Health Organization (WHO) estimated 
that, in 2007, of the 9.27 million new cases of TB worldwide, 1.37 million occured in persons 
with HIV (World Health Organization, 2009). In 2008, nearly 1 of 3 TB-related deaths (29%) 
worldwide was considered to be related to HIV infection, and TB contributed to 26% of the 
estimated deaths due to HIV infection. HIV has increased the incidence of TB by up to 
sevenfold in African countries (Williams et al., 2010). Countries in southern Africa are 
particularly affected, with over 50% of TB patients diagnosed each year being co-infected 
with HIV (Corbett et al., 2003; World Health Organization, 2007). In 2007, countries in sub-
Saharan Africa accounted for  nearly 80% of the estimated global burden of HIV infection–
associated TB. It has been reported that, TB is the commonest cause of death in hospitalized 
HIV-infected adults in sub-Saharan Africa (Sani et al., 2006; Lucas et al., 1993; Nelson et al., 
1993) and in another report, among HIV-infected patients not on ART, it was the commonest 
cause of adult hospitalization, in Nigeria (Habib et al., 1998). 
TB disease in persons with HIV infection can develop immediately after exposure (i.e. 
primary disease) or as a result of progression after establishment of latent TB infection. The 
risk of progression to active TB is highest in those with HIV coinfections (Lawn et al., 2011). 
While the lifetime risk of reactivation latent TB infection is 5% in HIV negative persons, the 
risk among HIV-infected persons has been estimated to be 10% per year. The interaction 
between HIV infection and tuberculosis is complex: HIV infection, by decreasing interferon-
gamma production, increases the risk for the development of active TB disease. Following 
the initial exposure, the rate of progression of TB infection to active disease is higher than 
40% in HIV positive patients compared to approximately 5% in HIV negative patients 
(Havlir & Barnes, 1999). On the other hand, M. tuberculosis enhances HIV replication and 
accelerates the natural progression of HIV infection by increasing cytokine production (in 
particular tumor necrosis factor-alpha).  
TB disease occurs among HIV–infected persons at all CD4
 
T lymphocyte counts, but the 
incidence increases as the count decreases. Also, the clinical, radiographic, and 
histopathologic presentation of HIV–related TB disease is influenced by the degree of 
immunodeficiency. With CD4
 
T lymphocyte counts >350 cells/μL, HIV positive TB appears 
like TB among HIV negative persons. The majority of patients have disease limited to the 
lungs. However, extrapulmonary disease is more common in HIV positive cases than in HIV 
negative ones and those with advanced immunosuppression (CD4
 
T lymphocyte count <200 
cells/μL) are more likely to have extrapulmonary or disseminated disease. 
Although HIV positive persons with TB may have the classic symptoms of TB (eg, 
productive cough, chest pain, shortness of breath, hemoptysis, fever, night sweats, and/or 
weight loss), many such patients have few symptoms or have symptoms that are even less 
specific. 
The radiographic findings of TB also depend on the degree of immunosuppression 
(Marchiori et al., 2005). In patients who have CD4 cell counts above 350-400 cells/μL, the 
findings tend to be similar to those without HIV infection. Most of these persons present 
with a classic reactivation TB radiographic pattern consisting of unilateral or bilateral upper 
lung zone reticulonodular infiltrates with or without cavitation. In more severely 
immunocompromised patients, the radiologic manifestations tend to resemble those of 
primary disease including areas of consolidation, miliary disease, pleural effusion, and 
lymph node enlargement (Laissy et al., 1998). Cavitation is less common but intrathoracic 
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adenopathy is more common in these individuals with advanced HIV/AIDS. Up to 20% of 
severely immunocompromised AIDS patients with pulmonary TB have radiographs that 
show normal findings (Boiselle et al., 2002). The small nodules and lymph node enlargement 
are the usual findings at high resolution CT. 
The diagnostic approach to TB in HIV positive person is same with those HIV negative ones. 
The gold standard diagnostic test for TB remains the isolation and identification of M. 
Tuberculosis by culture (Crothers et al., 2010). It is more sensitive than sputum smear, 
allowing detection of TB in sputum smear negative cases such as HIV positive patients. In a 
setting in South Africa, 49% of sputum smear negative HIV patients were sputum culture 
positive. All cultures positive for M. Tuberculosis should be sent for susceptibility testing to 
identify drug resistance. 
Typically, diagnostic evaluation of suspected TB includes 2 to 3 sputum specimens sent for 
acid fast bacillus (AFB) smear and, mycobacterial culture. The quality and number of 
collected specimens affect diagnostic results. A systemic review in 2007 concluded that, the 
average sensitivity of the first sputum slide (53,5%) increased following the addition of 
second slide (64.9%), but not further with a third slide (Mase et al., 2007). Sputum smear 
microscopy is the primary tool for TB diagnosis. However, a lower sensitivity in HIV-
patients is often seen due to their lower sputum bacillary load. Sputum microscopy may 
also be false-negative if the sputum concentration of mycobacteria is below 10,000 
organisms/mL. Alternative sample processing methods may increase sensitivity. A systemic 
review showed that centrifugation or overnight sedimentation with chemical processing 
increases sputum smear sensitivity (Steingart et al., 2006). Fluorescent microscopy (FM) is an 
alternative way to Ziehl-Neelsen (ZN) staining for the detection of AFB. The procedure is 
thought to be faster, more-cost effective, and more sensitive than ZN. In a study from 
Kenya, FM was twice as sensitive as ZN in HIV positive cases using the culture as a gold 
standard (Kivihya-Ndugga et al., 2003). An Indian study reported 26% more TB cases 
detected when FM was used compared to ZN in a population including 15% HIV positive 
patients (Prasanthi & Kumari, 2005). In many cases, especially those with advanced 
immunosuppression and low CD4 cell-counts, are unable to produce sputum 
spontaneously. In such patients, sputum induction by inhalation hypertonic solution should 
be performed. Mycobacterial blood cultures can be obtainable, especially in persons whose 
CD4 cell count is below 200 cells/μL and/or persons with evidence of disseminated disease. 
Nucleic-acid amplification (NAA) tests are useful in providing rapid identification of M. 
tuberculosis from sputum smear-positive specimens, but false-negative results can occur 
among patients with TB disease. The positive predictive value of NAA tests are decreased in 
persons who have sputum smear-negative results. Several reports indicate that in HIV 
patients, NAA tests may also be helpful for diagnosing TB when used on blood and urine 
(Kibiki et al., 2007; Rebollo et al., 2006; Torrea et al., 2005).  Despite its possible advantages, 
NAA diagnostics remain expensive, technically demanding and prone to contamination, 
especially in high-volume settings (Rewata et al., 2009). 
Current estimates are that one third of the world’s population is infected with M. 
Tuberculosis. Yet, to date, there is no gold standard for diagnosis of latent TB infection 
(LTBI). Traditionally, the tuberculin skin test (TST) has been used to measure delayed 
hypersensitivity reaction following intradermal injection of purified protein derivative 
(PPD). However, its use in the diagnosis of LTBI lacks both specificity and sensitivity. More 
recently, IFN-γ release assays (IGRA) such as QuantiFERON-TB Gold In-Tube and T-SPOT. 
TB has been developed (Lalvani et al., 2001). IGRA improve the specificity of LTBI diagnosis 
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by measuring cytokine production by immune cells to M. tuberculosis-specific proteins, 
transcribed from genes not found in Bacile Calmette-Guerin (BCG) and most other 
environmental mycobacteria. Early secreted antigenic target-6 and culture filtrate-10 are the 
two best studied to date and can improve the sensitivity of LTBI diagnosis to 96% compared 
with 69% achieved by TST. 
In principle, the treatment of TB in individuals with HIV infection should be the same as 
that for patients with TB who do not have HIV disease. Currently, treatment guidelines 
recommend that the duration of TB therapy should be the same for both HIV positive and 
HIV negative cases (Blumberg et al., 2003; Hopewell et al., 2006; World Health Organization, 
2003). Standard first-line therapy for TB with a 4-drug intensive treatment phase of 2 
months, followed by 4 months of treatment with a 2-drug regimen, is highly effective in 
patients with HIV infection–related TB. Initial treatment of presumed drug-sensitive TB 
consists of isoniazid (INH), rifampin (RIF) or rifampicin (RFB), pyrazinamide (PZA), and 
ethambutol (EMB). Pyridoxine (B6 vitamin) should also be given to avoid peripheral 
neuropathy side effect of INH. Persons with cavitary lung disease whose 2-month repeat 
sputum culture remains positive should receive additional initial phase treatment for a 
month or an additional 3-4 months of treatment (total of 9-12 months). Consultation with a 
TB expert should be obtained in persons with known drug-resistant (multi drug-resistant, 
MDR, or extensively drug-resistant, XDR) TB and in persons who are failing standard 4-
drug therapy, where drug-resistance is suspected. When results of species identification and 
susceptibility become available, drug selection can be tailored as needed. Because of the 
severity of TB disease among immunocompromised patients, directly observed therapy 
(DOT) is strongly recommended for patients with HIV–related TB.  
It has been reported that trimethoprim-sulfamethoxazole, given a month after initiation of 
anti-TB therapy, reduced mortality by 46% among HIV1– and HIV2 coinfected patients with 
TB (Wiktor et al., 1999). Use of trimethoprim-sulfamethoxazole appeared to reduce the risk 
of death by preventing gastrointestinal and respiratory infections. As a result, the WHO and 
the United Nations Joint Programme on HIV/AIDS (UNAIDS), recommend that patients 
with HIV infection–related TB be treated with trimethoprim-sulfamethoxazole during and 
after treatment for TB (Sterling et al., 2010). 
HIV infection is associated with high rates of recurrent TB, particularly in developing 
countries. However, in such settings, recurrent disease is more likely to be attributable to 
exogenous reinfection than to relapse. A course of isoniazid after completion of standard 
anti-TB treatment has been associated with lower rates of TB recurrence, particularly among 
HIV-infected persons. Although this strategy has been proven to be effective in settings with 
a high incidence of TB and HIV infection, it is often not provided because of logistical 
constraints (Sterling et al., 2010). 
Among HIV-infected persons who receive a diagnosis of TB and do not receive HAART, the 
mortality rate is high (as high as 91% among persons with AIDS). Initiation of HAART is 
associated with improved survival among all HIV infected persons, including those with 
TB. It is therefore recommended that HIV-infected patients with TB receive treatment for 
both diseases, regardless of their CD4 lymphocyte count. However, the optimal timing of 
HAART initiation in relation to the time of anti-TB therapy initiation is unclear, but it is 
generally recommended to wait at least 2 weeks or longer depending on the degree of 
immunocompromised status (Centers for Disease Control and Prevention, 2009).  
In persons on ART, drug interactions can occur particularly between the rifamycins and 
both protease inhibitors and non-nucleoside reverse transcriptase inhibitors. As a result of 
www.intechopen.com
 
Microbes, Viruses and Parasites in AIDS Process 94
this interaction, decreased drug levels are associated with the development of resistance by 
both HIV and M. tuberculosis, whereas increased drug levels are associated with toxicity. In 
addition, persons receiving dual therapy for HIV infection and TB may develop the immune 
reconstitution syndrome. This shows a paradoxical reaction presenting as a temporary 
exacerbation of clinical and radiographic features which appears to be more common 
among those starting ART within 6 weeks of initiating anti-TB therapy and among those 
with disseminated TB.  
TB prevention strategies with known efficacy include rapid identification and treatment of 
active TB cases (in source patients), infection-control measures to reduce nosocomial 
transmission of TB, isoniazid preventive therapy during latent TB infection, and ART to 
reduce the incidence of TB among HIV-infected patients (Chamie et al., 2010). Prevention of 
HIV infection is necessary to control TB. ART is one of the most potent tools in TB 
prevention, and increasing ART access in countries with a high TB burden is a necessary 
step in reducing TB incidence. Observational cohort studies have shown reductions in the 
risk of TB among persons receiving ART (Lawn et al., 2009). Treatment of latent TB, 
primarily studied using isoniazid preventive therapy in HIV-infected patients who have 
positive tuberculin skin test results, clearly reduces the incidence of active TB. In persons 
with HIV, ≥5 mm of induration at 48-72 hours is considered to represent a positive purified 
protein derivative (PPD) or TST. IFN-γ release assays (IGRAs) can also be used to diagnose 
LTBI. Since HIV infection is associated with a high risk for progression to TB, current 
guidelines recommend that persons with either a positive TST or IGRA should be 
considered infected with M. tuberculosis (Centers for Disease Control and Prevention, 2009).  
Persons with HIV infection should receive INH either daily or twice weekly plus pyridoxine 
for 9 months.  
3.2 Non-tuberculous mycobacteria 
Since the beginning of the AIDS epidemic, nontuberculous mycobacterial (NTM) infections 
have been reported with increasing frequency in HIV-infected patients. The majority of 
these infections have been caused by members of the Mycobacterium avium complex (MAC). 
Occasionally, M. kansaii M. xenopi, M. fortuitum, M.chelonae or M. sherrisii also causes 
pulmonary disease. MAC includes at least two species, Mycobacterium avium and 
Mycobacterium intracellulare and also M. avium is composed of several subspecies. In a report 
including a total of 2,269 cases with AIDS and disseminated nontuberculous mycobacterial 
infection; in 96% of cases, infection was caused by MAC (Horsburgh & Selik, 1989). 
However, Raszka et al. reported that, among the 92 patients infected with HIV and NTM 
organisms identified; MAC was recovered from 50 (77%) of the 65 NTM-positive cultures of 
blood or bone marrow, while MAC and other non-avium NTM accounted for 18% and 5% 
of the isolates, respectively and the authors concluded that those data demonstrate that 
HIV-positive patients develop disseminated disease with NTM other than M. avium more 
frequently than has been previously reported (Raszka et al., 1995).  
The disease may manifest as disseminated infection, soft tissue infection, chronic 
pneumonia, or hypersensitivity pneumonitis, and isolated MAC pulmonary disease is very 
rare. Most patients have disseminated multiorgan infection. The risk of developing 
disseminated MAC increases as the CD4 lymphocyte count declines and more than 95% of 
cases occur when the lymphocyte count is 50 cells/µ/L or less. Unlike TB, disseminated 
MAC is usually a primary infection and is often preceded by a period of respiratory or 
gastrointestinal colonization after ingestion or inhalation of contamined food or water. The 
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clinical findings of disseminated MAC include fever, anorexia, night sweats, weight loss, 
abdominal pain, hepatosplenomegaly, lymphadenopathy, chronic diarrhea and anemia. The 
radiologic findings of pulmonary MAC include consolidation, cavities, nodules, 
bronchiectasis and adenopathy (Erasmus et al., 1999). While focal infiltration is extremely 
rare, a frequent finding is endobronchial lesion without pneumonia (Mehle et al., 1989; 
Salama et al., 2003). Pleural involvement in nontuberculous mycobacterium infection has 
also been reported rarely (Haider et al., 2009). 
The diagnosis of pulmonary MAC is based on clinical, microbiological, and radiographic 
findings (Griffith et al., 2007). It is based on compatible clinical signs and symptoms coupled 
with the isolation of MAC from cultures of blood, bone marrow, or other normally sterile 
tissue or body fluids. The positive culture of sputum or BAL for MAC, may not be indicative 
for either pulmonary or disseminated disease. Culture of blood is the most useful diagnostic 
procedure to evaluate MAC infection. The sensitivity of blood cultures for disseminated 
MAC has ranged from 86% to 98%. Recently, Singh et al studied a rapid PCR method for the 
species-specific diagnosis of M. tuberculosis and its differentiation from other mycobacteria, 
and the authors concluded that, the combination of genus-specific PCR primers with the 
novel early-secreted antigen-6 primer set could provide accurate and rapid diagnosis of 
mycobacteriosis (Singh et al., 2007).  
The therapy for pulmonary disease due to MAC includes three oral antimicrobials: a 
macrolide (clarithromycin or azithromycin), ethambutol, and a rifamycin (rifampin or 
rifabutin). Clarithromycin is the preferred first agent, but azithromycin can be substituted if 
needed, although its in vitro activity is less than clarithromycin. Ethambutol is the 
recommended second agent and should be combined with one of these macrolides. 
Rifabutin is also recommended as a third agent of combination therapy (Benson et al., 2003; 
Gordin et al., 1999). In a study in which clarithromycin (500 mg bid.) plus ethambutol (1,200 
mg/d), with or without rifabutin (300 mg/d) was evaluated, rifabutin was found to no 
impact on bacteriologic response or survival but may protect against development of 
clarithromycin resistance in those who respond to therapy (Gordin et al., 1999). In another 
multicenter, randomized trial, Benson et al. reported that the addition of rifabutin to 
clarithromycin plus ethambutol, had improved the survival (Benson et al., 2003). A third or 
fourth drug among the fluoroquinolones (ciprofloxacin or levofloxacin) or parenteral 
amikacin may be given if rifabutin cannot be used or in patients with advanced 
immunosuppression and high mycobacterial burden (Centers for Disease Control and 
Prevention, 2009). Duration of treatment is for 12 months beyond the time that the patient’s 
cultures convert to negative, which usually equates to 18 to 24 months of therapy 
(Kasperbauer & Daley, 2008).  
4. Fungal infections 
4.1 Pneumocystis jiroveci 
PCP (shortened for Pneumocystis pneumonia) caused by Pneumocystis jiroveci (formerly 
classified as P. carinii), still remains the most common opportunistic infection in patients 
infected with HIV. Once thought to be a parasite, genomic analysis revealed that P. jiroveci is 
in fact a fungus that infects only humans. Before the widespread use of primary PCP 
prophylaxis and effective ART, PCP occurred in 70%–80% of patients with AIDS. The use of 
combination antiretroviral therapy and PCP prophylaxis has contributed to the dramatic 
declines. Nevertheless, despite a decrease of its overall incidence as a result of use of 
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combination ART and PCP prophylaxis, PCP remains the most frequent AIDS-defining 
diagnosis in the United States (Thomas, 2004). Pneumocystosis would cause life-threatening 
pneumonia in patients without chemoprophylaxis, without HAART or unaware of their 
HIV infection.  
The risk factors for the development of PCP among HIV-infected persons include a CD4 
lymphocyte count less than 200cells/µL (approximately 90-95% of cases), a history of PCP 
and oropharyngeal candidiadis (Phair et al., 1990; Stansell et al., 1997). Clinical presentation 
of patients affected with Pneumocystis pneumonia differs among HIV and non-HIV 
immunosuppressed patients. HIV patients tend to present with subacute onset of 
progressive dyspnea, nonproductive or minimally productive cough, low-grade fever and 
malaise. However, up to 7% of these patients can be asymptomatic. In contrast, patients that 
are immunocompromised but HIV-negative usually present more acutely, with substantial 
dyspnea, fever, chills and some may initially present in urgent need of mechanical 
ventilation. The fulminant pneumonia observed among non-HIV–infected patients is less 
common. Approximately 90% of patients with PCP have an elevated serum LDH level, but 
this may occur with other pulmonary diseases, especially mycobacterial and fungal 
infections (Rosen, 2008). Other tests, including S-adenosylmethionine levels, KL-6 and beta-
D-glucan, have been reported as the diagnostic tests for PCP (Skelly et al., 2008; Tasaka et 
al., 2007). Hypoxemia, the most characteristic laboratory abnormality, might range from 
mild-to-moderate (room air arterial oxygen [pO2] of >70 mm/Hg or alveolar-arterial O2 
difference, [A-a] DO2 <35 mm/Hg) to moderate-to-severe levels (pO2 <70 mm/Hg or [A-a] 
DO2 >35 mm/Hg). Recently, Sage et al. studied the prognostic value of C-reactive protein 
(CRP) in HIV-infected patients with PCP and reported that, higher CRP values were more 
suggestive of bacterial infection, but the finding lacked specificity and was not useful in 
distinguishing between PCP and other causes of respiratory infection. Moreover, in patients 
with PCP higher CRP values were associated with more severe disease and a poor outcome, 
suggesting CRP measurement might be used prognostically (Sage et al., 2010).  
The chest X-ray (CXR) usually shows bilateral, symmetrical reticular or granular opacities. 
Less frequently, PCP may present with unilateral or asymmetrical opacities. Some patients 
with PCP have nodular densities, lobar consolidation or normal CXR findings. Cystic 
abnormalities and spontaneous pneumothorax in patients with known or suspected HIV 
infection are usually caused by PCP, but may also be caused by TB. Cavitation or pleural 
effusion is uncommon in the absence of other pulmonary pathogens or malignancy, and the 
presence of a pleural effusion might indicate an alternative diagnosis. At times clinical 
symptomatology, specifically in the absence of significant CXR findings, initiates more 
sensitive radiological approaches such as high-resolution chest CT. The most typical 
findings on chest CT are bilateral ground glass opacities. Less-common features can include 
reticular, granular, and cystic lesions. 
Since Pneumocystis cannot be cultured, the gold standard for diagnosis is microscopic 
visualization of the organism of the characteristics cysts or trophic forms on stained 
respiratory specimens including expectorated or induced sputum, pulmonary secretions 
obtained by nasotracheal suction, percutaneous aspiration of the lung parenchyma; via 
flexible bronchoscopy including BAL, washing, brushing and transbronchial biopsy; or via 
thoracoscopic or open-lung biopsy (Carmona & Limper, 2011). Induced sputum can be the 
first diagnostic procedure. The reported diagnostic sensitivities of various methods are; 
induced sputum <50 to >90%, bronchoscopy with bronchoalveolar lavage 90%–99%, 
transbronchial biopsy 95%–100%, and open lung biopsy 95%–100%. PCR–based techniques 
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have also been employed and have been reported to be more sensitive and less specific 
leading to higher false-positive rates. Therefore, clinical correlation is always necessary. 
Since messenger RNA (mRNA) is less stable than DNA, if the patient is not actively infected 
with viable organisms, the mRNA should be largely degraded and no longer detected. 
Hence, new techniques that detect (mRNA) have been proposed as surrogate markers for 
organism viability. Recent data from HIV patients with suspected Pneumocystis pneumonia 
using reverse-transcriptase PCR targeting a heat shock protein of Pneumocystis mRNA 
(Phsb1) have yielded a diagnostic sensitivity and specificity of 100% and 86%, respectively, 
in BAL specimens (de Oliveira et al., 2007).  
In patients without known contraindications, trimethoprim-sulfamethoxazole (TMP-SMX) is 
the drug of choice regardless of the severity of disease. The standard dose is 15-
20mg/kg/day of TMP and 75-100 mg/kg/day of SMX. However in a recent study, it has 
been reported that, treatment of PCP in adult HIV-infected patients with trimethoprim 10 
mg/kg/day-sulfamethoxazole 50mg/kg/day appears to have comparable efficacy to 
treatment (Thomas et al., 2009). 
For severe cases, the intravenous (IV) form is preferred over the oral formulation. However, 
IV regimen can be switched to oral route, once clinical improvement is achieved. Standard 
treatment for PCP is 21 days; some persons will have responded well before this time and 
therapy can often be stopped and others will remain symptomatic and require continued 
therapy. Dose reductions are necessary for patients with renal and liver failure. Alternatives 
to TMP-SMX include intravenous or aerosolized pentamidine, clindamycin plus 
primaquine, trimethoprim plus dapsone and atovaquone solution. Aerosolized pentamidine 
has been associated with the development of disseminated disease, likely due to poor 
systemic levels. The IV formulation of pentamidine has better coverage and greater efficacy 
than the aerosolized route. However, it is at times poorly tolerated due to side effects that 
include hypotension, hypoglycemia and pancreatitis (Carmona & Limper, 2011). Another 
important aspect of Pneumocystis treatment is the use of corticosteroids. The administration 
of corticosteroids at the beginning of the therapy reduces the likelihood of respiratory 
failure, the deterioration of oxygenation, and death in patients with moderate-to-severe 
pneumonia. Patients usually benefit from therapy especially with respiratory insufficiency 
(Rosen, 2008). 
4.2 Histoplasmosis 
Histoplasmosis is caused by the dimorphic fungus Histoplasma capsulatum and the infection 
causes significant morbidity and mortality in HIV-infected individuals. Histoplasma 
capsulatum is reported to exist throughout the world, although the Mississippi and Ohio 
River catchments of the United States represent areas of greatest endemicity (Kauffman, 
2007). It is the most frequent opportunistic infection due to HIV in French Guiana, along 
with tuberculosis, and the first cause of AIDS-related death (Couppie et al., 2004; Lewden et 
al., 2004). Disseminated histoplasmosis usually occurs among persons with CD4
 
lymphocyte 
counts <150 cells/μL; while localized pulmonary histoplasmosis might occur when CD4 
lymphocyte counts >300 cells/μL (Centers for Disease Control and Prevention, 2009).  
In HIV-infected patients the most common clinical presentation is disseminated multiorgan 
disease. Common symptoms include fever, chills, anorexia, fatigue, weight loss, cough, 
chest pain, and dyspnea and specific symptoms and signs related to organ involvement. In a 
study of 200 cases of AIDS-related histoplasmosis, most patients had fever, 
lymphadenopathies, and pulmonary and digestive symptoms whereas neurological signs 
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and skin/mucosal locations were less common (Huber et al., 2008). The radiologic findings 
of patients with pulmonary involvement are diffuse interstitial or reticulonodular infiltrates. 
The patients with disseminated histoplasmosis may have normal CXR. Several laboratory 
abnormalities include increased lactate dehydrogenase, elevated liver enzymes, especially 
alkaline phosphatase, markedly increased ferritin, and pancytopenia.  
Although the isolation and identification of fungus provides a definitive diagnosis, isolation 
can take 2–4 weeks and hence, the Histoplasma polysaccharide antigen (HPA) test is an initial 
test for the diagnosis of disseminated histoplasmosis (Centers for Disease Control and 
Prevention, 2009). Detection of circulating HPA in urine, serum, and other body fluids has an 
increasingly important role in the rapid diagnosis of disseminated histoplasmosis. Sensitivity 
is greater in urine than serum and the sensitivity of the urine assay for the diagnosis of 
disseminated histoplasmosis is approximately 90% (Wheat et al., 2002). In patients who have 
other fungal infections, including coccidioidomycosis, blastomycosis, paracoccidioidomycosis, 
and penicilliosis false positive reactions for HPA in urine may occur. The HPA test is often 
negative in isolated pulmonary disease. In such patients, direct examination and culture of 
sputum, BAL, or transbronchial biopsy can be performed. Bone marrow, lymph node, liver, or 
a skin or mucous membrane lesion provides other diagnostic sources.  
Amphotericin B, either the deoxycholate formulation or liposomal amphotericin B is 
currently considered the drug of choice in HIV-positive patients with severe or 
disseminated histoplasmosis. Once clinical improvement was achieved, Amphotericin can 
be switched to itraconazole to complete at least a 12-month therapy course. 
4.3 Aspergillosis 
Aspergillosis, an infrequent but commonly fatal infection among HIV-infected patients, is a 
mycotic disease caused by Aspergillus species, usually Aspergillus fumigatus. In a review 
including 342 cases of pulmonary aspergillosis among HIV-infected patients, Aspergillus 
fumigatus was the most common pathogen (95% of the cases), while strains of Aspergillus 
flavus, Aspergillus niger, and Aspergillus terreus were less common (Mylonakis et al., 1998).  
The major risk factors for aspergillosis include, neutropenia and steroid treatment, whereas 
the other risk factors are low CD4 lymphocyte count, previous pneumonia, opportunistic 
infections, especially those involving the lungs, such as PCP and CMV infection and use of 
broad spectrum antibacterial therapy, alcohol and marijuana. Clinical manifestations of 
aspergillus infections include: allergic bronchopulmonary aspergillosis, intracavitary 
aspergilloma, chronic forms of pulmonary aspergillosis, tracheobronchitis and 
rhinosinusitis, and invasive pulmonary aspergillosis as the most severe clinical presentation. 
The two major syndromes that have been described are: respiratory tract disease, associated 
with fever, cough, dyspnea, stridor or wheezing caused by airway constriction and invasive 
parenchymal infection which is usually fatal.  
Although the prevalence of invasive aspergillosis among patients infected with HIV is lower 
than in other immunocompromised patients (Mylonakis et al., 1998), invasive pulmonary 
aspergillosis is still a life-threatening opportunistic infection in the advanced stage of HIV 
infection. Most patients have a CD4 lymphocyte count lower than 50 cells/µL. Holding et al. 
reported that, among 35,252 HIV-infected patients, the incidence of aspergillosis was 
350/100.000 (Holding, 2000).  
The radiologic findings include cavities, nodules and localized or diffuse infiltrates. Since its 
presence in nasopharyngeal secretions, sputum and BAL fluid may represent contamination 
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or colonization, the definitive diagnosis of aspergillosis requires identification of the fungus 
on a biopsy specimen with the documentation of tissue invasion and the presence of 
appropriate clinical signs and symptoms. In a report, among 45 patients with AIDS and 
respiratory cultures positive for aspergillus, invasive pulmonary aspergillosis was 
documented in only four of these patients (Pursell et al., 1992). However, a presumptive 
diagnosis of respiratory tract disease can be made in the absence of a tissue biopsy if 
Aspergillus spp. are cultured from a respiratory sample, a compatible lesion or syndrome is 
present, and no alternative causative process is identified. Although serum galactomannan 
antigen testing and PCR-based techniques may be useful, they have not been studied in 
patients with HIV.  
Voriconazole is the first-line recommended therapy for invasive aspergillosis. Conventional 
or lipid formulations of Amphotericin B, caspofungin and posaconazole are the other 
alternatives for antifungal therapy.  
4.4 Coccidioidomycosis 
Coccidioidomycosis is a fungal disease caused by, Coccidioides immitis and Coccidioides 
posadasii. The disease is endemic in southwestern US and northern Mexico (Pappagianis, 
1988). Although coccidioidomycosis is uncommon in HIV-infected patients, in endemic 
regions, it is a common opportunistic infection in HIV–infected individuals. In a study 
performed by Masannat et al, among 257 HIV–infected patients seen over a 64-month 
period, 29 cases (11.3%) of coccidioidomycosis were identified (Masannat & Ampel, 2010). 
The incidence of coccidioidomycosis has declined as a result of ART (Woods et al., 2000).   
The risk factors for coccidioidomycosis include low CD4 cell counts (<250 cells/µL), black 
race, a history of oropharyngeal or esophageal candidiasis, whereas a reduced risk is 
associated with protease inhibitor therapy.  
The most common clinical presentations of coccidioidomycosis in HIV-infected patients are 
disseminated disease, diffuse pneumonia and meningitis. Disseminated coccidioidomycosis, 
defined as disease that has spread beyond the thoracic cavity, is frequent among patients 
with HIV infection and associated with generalized lymphadenopathy, skin nodules or 
ulcers, peritonitis, liver abnormalities, and bone and joint involvement. The most common 
radiographic finding of coccidioidomycosis is reticulonodular infiltrates. Focal infiltrates are 
less common. The other findings include nodules, adenopathy, cavities and pleural effusion.  
The mainstays of diagnosis of coccidioidomycosis are serologic testing, histopathological 
identification, and culture (Ampel, 2005). In cases of pulmonary coccidioidomycosis, results 
of culture of respiratory specimens (sputum, BAL fluid, or transbronchial biopsy) are 
frequently positive. The diagnosis can be established by also, demonstration of the typical 
spherule on histopathological examination of involved tissue. Although, serologic tests are 
useful, it is less reliable for patients with HIV infection than for immunocompetent patients 
and the results may not always be positive. 
Amphotericin B is the preferred initial therapy for patients with isolated pulmonary disease 
and disseminated disease without meningeal involvement (Centers for Disease Control and 
Prevention, 2009). Amphotericin B should be continued until clinical improvement, and 
then the therapy can be switched to fluconazole or itraconazole. In patients with mild 
disease such as focal pneumonia, fluconazole or itraconazole may be alternative agents. 
Flucanozole is the recommended drug for coccidioidal meningitis, since the reported 
success of this agent is approximately 80% (Galgiani et al., 1993).  
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4.5 Candidiasis  
Mucocutaneous candidiasis is frequently one of the first signs of HIV infection and 90% of 
patients with AIDS will develop oropharyngeal candidiasis at some time during their illness 
(Vazquez, 2000). However, pulmonary candidiasis is an uncommon manifestation among 
HIV-infected patients. In 1987, data from the Centers for Disease Control AIDS data base 
indicated a 50% prevalence of oropharyngeal candida infection, a 10% rate of esophageal 
infection, and 5% rate of bronchopulmonary infection among AIDS patients (Selik et al., 
1987). Due to the rare occurence of pulmonary candidiasis, clinical features among HIV-
infected patients are not well documented.  
4.6 Blastomycosis 
Blastomycosis is a fungal infection acquired via inhalation of Blastomyces dermatitidis. The 
majority of cases occur in central, southeastern, and mid-Atlantic areas of the United States. 
Of the endemic fungi, blastomycosis is an uncommon disease among HIV-infected patients.  
The most common clinical manifestation of blastomycosis in immunocompetent hosts 
include skin and lung involvement which mimic those of bacterial infection. However, it is 
potentially much more severe and is characterized by disseminated multiple organ 
involvement including frequent involvement of the central nervous system, adult 
respiratory distress syndrome and/or miliary pulmonary involvement. In the largest case 
series reported to date, among 15 HIV-infected patients, the patterns of the disease was 
localized pulmonary involvement in seven patients, disseminated or extrapulmonary 
blastomycosis in eight patients and in 40% of patients central nervous system involvement 
was observed (Pappas et al., 1992). 
In HIV-infected patients, blastomycosis tends to occur in persons CD4 counts less than 200 
cells/mm3. In the largest case series mentioned above, among 15 patients, only one patient 
had a CD4 lymphocyte count greater than 200 cells/µL (Pappas et al., 1992).  
The definitive diagnosis requires culture of respiratory specimens or tissue samples. The 
visualization of characteristic budding yeast form is also highly suggestive for diagnosis. 
Sputum analysis in most cases aids in the diagnosis, but bronchoscopy and/or tissue biopsy 
should be considered if the suspicion of blastomycosis is high and sputum analysis is 
inconclusive, negative or not possible (Patel et al., 1999). There is no serologic test for 
blastomycosis that has been validated in HIV-infected patients.  
Intravenous amphotericin B is the drug of choice in patients with severe or disseminated 
blastomycosis. Amphotericin should be continued until a total of 1.5 to 2.5 g dose. Then, 
with the improvement of patient, the therapy can be switched to oral itraconazole.  
4.7 Cryptococcosis 
Cryptococcosis is a disease caused by Cryptococcus neoformans a unique environmental 
fungus and an encapsulated budding yeast. In AIDS patients Cryptococcus neoformans, 
serotype D and in particular serotype A, is the major cause of cryptococcosis throughout the 
world (Sugar, 1991). 
Although the lungs are the portal of entry of the infection, the most common clinical 
presentation of cryptococcosis among HIV-infected patients is meningitis. In a study 
performed by Chuck et al., 84% of patients with HIV infection and cryptococcosis had 
meningitis, whereas 4% of patients had isolated pneumonia (Chuck & Sande, 1989). The 
majority of cases of cryptococcal disease occur in persons with a CD4 cell count below 200 
www.intechopen.com
 
AIDS and Opportunistic Infections 101 
cells/μL, usually below 50 cells/μL. In a series of 15 HIV-infected patients with pulmonary 
cryptococcosis,  the CD4 lymphocyte count was low in all cases (median, 24/μL) (Ballou et 
al., 1997). With the use of combination ART, the incidence of cryptococcosis has dramatically 
declined.  
The clinical manifestations of pulmonary cryptococcosis include fever, cough, dyspnea, 
expectoration, chest pain and hemoptysis. The most common radiographic finding is diffuse 
interstitial opacities, while others are focal interstitial abnormalities, alveolar opacities, 
adenopathies, cavitary lesions, and pleural effusions. Solitary pulmonary nodules, 
pulmonary masses, a milliary pattern and pneumothorax have also been reported.  
The inital diagnostic test for cryptococcosis is cryptococcal antigen test, which is sensitive 
and specific. However, patients with isolated pulmonary disease may have a negative result. 
The test can be performed on serum, cerebrospinal fluid and respiratory samples. Blood 
fungal cultures are also specific and should be performed. The diagnosis of pulmonary 
cryptococcosis can be made by culture of sputum, BAL fluid, pleural fluid and 
transbronchial biopsy specimen. The measurement of cryptococcal antigen in the BAL can 
be a rapid, simple way to make the diagnosis (Baughman et al., 1992).  
The treatment of meningitis and pneumonia is same and the recommended initial treatment 
for acute disease is amphotericin B, usually combined with flucytosine, for a 2-week 
duration followed by fluconazole (400 mg daily) alone for an additional 8 weeks (Centers for 
Disease Control and Prevention, 2009). Following this period, as a maintenance therapy, 
fluconazole (200 mg daily) for life or until the CD4 cell count rises above 200 cells/μL for at 
least 6 months should be continued.  
4.8 Penicilliosis 
Penicilliosis is caused by Penicillium marneffei, a dimorphic fungus which is endemic in 
Southeast Asia. Although it was a rare and sporadic disease before the HIV pandemic, 
penicilliosis is now the third most common AIDS-defining illness (after TB and 
cryptococcosis) in South East Asia (Fisher et al., 2004).  
Although direct inoculation through skin can occur, inhalation is the main route of exposure. 
Most of the patients show absolute CD4 count less than 100 cells/µL (Maniar et a., 2005).  
Penicillium marneffei can cause focal or disseminated infection. The common presenting 
symptoms and signs of infection are: fever of unknown origin, anemia, weight loss, 
hepatosplenomegaly, lymphadenopathy and skin eruptions. The skin lesions commonly 
appear as papules (characteristically with central umbilication, resembling molluscum 
contagiosum), nodules, or necrotic lesions, and they are predominantly located over the face 
and upper trunk (Ustianowski et a., 2008). The most common radiographic finding is 
interstitial opacities, the other findings may include nodules, cavities and pleural effusion. 
In a study from Taiwan, in which  etiology of cavitary lung lesions in patients with HIV 
infection was evaluated, fungi were the most common etiology (42.0%), followed by bacteria 
(29.6%) and mycobacteria (25.9%) and of the fungal pneumonias, 19 (55.9%) were caused by 
Penicillium marneffei as the most common agent (Lin et al., 2009). Definitive diagnosis 
requires culture of the pathogenic fungus from clinical specimens. Among all the clinical 
specimens studied, the bone marrow gives the highest yield for culture, approaching 100%, 
followed by skin biopsy (90%) and blood culture (76%) (Supparatpinyo et al., 1994). 
Serologic testing including various types of antigen and antibody testing specific to P. 
marneffei have been described but is of limited utility in penicilliosis (Wong  & Wong, 2011). 
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PCR assay specific for P. marneffei has been developed in research setting but is not available 
for routine clinical use (Pornprasert et al., 2009).  
The mainstay of therapy is amphotericin B (2 weeks) followed by itraconazole (10 weeks). 
Since relapse is common, secondary prophylaxis should be maintained until a CD4 count of 
greater than 200 cells/µL for at least 6 months. 
5. Viral infections  
Although a variety of viruses can cause pulmonary disease in HIV-infected patients, 
cytomegalovirus (CMV) is the most frequent agent of viral pneumonia. Pneumonia due to 
herpes simplex virus, varicella zoster virus, adenovirus, respiratory syncytial virus and 
parainfluenza virus is uncommon.  
5.1 Cytomegalovirus 
Cytomegalovirus (CMV) disease is a frequent opportunistic infection that usually occurs in 
the late stages of HIV infection as a result of reactivation of latent infection rather than new 
infection. It has been reported that, before ART, 21–44% of patients developed CMV-
associated disease at some point during the course of HIV infection and with the use of 
ART, the incidence of CMV disease has declined by 75–80%, and it is now estimated to be 
0.75–3.2 cases per 100 person-years (Jabs et al., 2007; Salmon-Ce´ron et al., 2000; Salzberger 
et al., 2005). The most common clinical manifestations of CMV are retinitis and 
gastrointestinal disease (colitis or esophagitis). CMV pneumonia is uncommon and has been 
observed in only 0.24–8% of HIV-infected patients (Erice et al., 2003; Rodriguez-Barradas et 
al., 1996). Most of the patients have CD4 count less than 50 cells/µL. The chest radiograph 
findings include diffuse interstitial infiltrates, alveolar infiltrates or rarely pleural effusion.  
In HIV-infected patients, the presence of CMV in BAL fluid is not usually predictive of CMV 
pneumonia and a definitive diagnosis depends on the documentation of CMV infection in 
lung tissue specimens. Diagnosis of CMV pneumonitis should be made in the setting of 
pulmonary interstitial infiltrates and identification of multiple CMV inclusion bodies in lung 
tissue, and the absence of other pathogens. Neither BAL fluid nor transbronchial biopsy 
culture are sufficient to make the diagnosis of CMV pneumonitis (Huang & Crothers, 2009). 
Although there is limited data, the treatment options for CMV pneumonia include 
ganciclovir, foscarnet, cidofovir or valganciclovir. The duration of therapy is unknown, but 
a 2-3 weeks course is recommended. 
6. Parasitic infections 
Although, Toxoplasma gondii, Strongyloides stercoralis, microsporidia, cryptosporidium can 
cause pneumonia, among HIV-infected patients, parasitic pneumonia is an uncommon 
disease. 
6.1 Toxoplasma gondii 
Toxoplasma gondii, is the most common cause of parasitic pneumonia. Cerebral 
toxoplasmosis is the most common form of clinical manifestation, followed by ocular 
toxoplasmosis and pulmonary toxoplasmosis. As a result of widespread utilization of 
trimethoprim-sulphamethoxazole as primary PCP prophylaxis in AIDS patients, which is 
also effective against Toxoplasma gondii, there has been a fall in the prevalence of pulmonary 
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toxoplasmosis. Pulmonary toxoplasmosis (PT) is most commonly seen in patients with 
advanced disease (Renold et al., 1992). In an  autopsy study of 78 cases of toxoplasmosis,  
the risk factors were founded as;  intravenous drug addiction, homosexuality or bisexuality 
and multiple blood transfusions (Hofman et al., 1993). Bilateral interstitial infiltrates is the 
most frequent finding on chest radiography; however, other abnormalities including 
nodular densities and pleural effusion and/or pneumothorax may also occur. An elevated 
LDH is a common laboratory finding. In a large study of 64 HIV-infected patients with PT, 
the clinical features usually included fever, cough, and dyspnea and the radiological 
findings were mainly diffuse interstitial infiltrates (Rabaud et al., 1996). Since clinical and 
radiological abnormalities are not specific, the diagnosis of pulmonary toxoplasmosis is 
difficult. The diagnosis can be established by direct examination (by Giemsa staining or 
indirect immunofluorescence with a monoclonal antibody to membrane antigen P-30) 
and/or tissue or BAL fluid culture. Although, PCR for detecting T. gondii in BAL samples 
have been studied, the diagnostic utility of this test is unclear (Lavrard et al., 1995; Petersen 
et al., 2006). The treatment of PT is similar to that for central nervous system disease and the 
first-line treatment is pyrimethamine plus sulfadiazine. Leucovorin is recommended for the 
hematologic toxicities associated with pyrimethamine. Clindamycin plus pyrimethamine is 
the alternative regimen.  
6.2 Other parasites 
Strongyloides stercoralis is an intestinal nematode which usually induces a silent or limited 
intestinal infection in immunocompetent hosts. It can also cause hyperinfection syndrome or 
disseminated disease in immunocompromised patients (Kramer et al., 1990). However, 
disseminated infection of Strongyloides stercoralis to the lung is extremely rare (Armignacco 
et al., 1989; Glezerov & Masci, 1990; Gomples et al., 1991; Makris et al., 1993). The common 
symptoms and signs are dyspnea, cough, sputum, wheezing and hemoptysis. In patients 
with the hyperinfection syndrome and massive Strongyloides infection, adult respiratory 
distress syndrome with respiratory failure that requires mechanical ventilation may 
develop. Chest radiography findings include reticulonodular pattern, diffuse bilateral 
interstitial opacities and alveolar opacities. The diagnosis is established by the identification 
of Strongyloides larvae on BAL fluid. The recommended treatment is ivermectin plus 
albendazole. 
Microsporidia and cryptosporidium are other parasities which can rarely cause respiratory 
tract disease. Cryptosporidiosis is a disease caused by a coccidial parasite of the genus 
Cryptosporidium. Pulmonary cryptosporidiosis is a rare complication of intestinal 
cryptosporidiosis in HIV-infected patients (Corti et al., 2008). The most frequent symptoms 
are cough, fever and dyspnea. Several respiratory infectious agents, mainly P. carinii and 
Cytomegalovirus may coexist (Brea Hernando et al., 1993). The major clinical manifestation of 
microsporidiosis is the involvement of gastrointestinal tract like cryptosporidiosis and it can 
rarely cause pulmonary symptoms (Remadi et al., 1995). The diagnosis of both diseases is 
made by the visualization of the organism on the respiratory specimen.  
7. Conclusion 
Human immunodeficiency virus (HIV), the cause of AIDS, has in the 30 years since its 
discovery spread rapidly to every region in the world. Since the beginning of epidemic, more 
than 65 million people have been infected with HIV and about 25 million people died from 
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AIDS. The lungs are principal target of HIV-associated complications and, accordingly, a 
major source of morbitidy and mortality. The spectrum of pulmonary manifestations includes 
bacterial infections, viral infections, mycobacterial infections, protozoal infections, fungal 
infections, malignancies (eg, Kaposi sarcoma, lymphoma), and other disorders (eg, pulmonary 
hypertension, lymphocytic interstitial pneumonitis). Among HIV-associated pulmonary 
complications, opportunistic pneumonias are major cause of morbitidy and mortality. 
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